bcma car-nk cells
Cell therapyexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Nov 13, 2022 (NCT05652530)
Timeline
2020s
- Jan 1, 2022
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Tumor necrosis factor receptor superfamily member 17Immunity, passive
TNFRSF17 immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06045091 | Early Phase 1 (Phase 1) | Jul 4, 2023 | Hrain Biotechnology Co., Ltd., Second Military Medical University |
| NCT05652530 | Early Phase 1 (Phase 1) | Nov 13, 2022 | Shenzhen Pregene Biopharma Co., Ltd. |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Hrain Biotechnology Co., Ltd. | For profit | 1 | 1 | 1 | 2023 |
| Second Military Medical University | Government | 1 | 0 | 1 | 2023 |
| Shenzhen Pregene Biopharma Co., Ltd. | For profit | 1 | 1 | 1 | 2022 |
3 organizations
Page 1 / 1